Obesity and the risk of venous thromboembolism after major lower limb orthopaedic surgery: a literature review
U Gurunathan, M Barras, C McDougall… - Thrombosis and …, 2022 - thieme-connect.com
The risk of venous thromboembolism following total joint arthroplasty is significantly greater
than those of other types of elective orthopaedic procedures. This risk is increased in obesity …
than those of other types of elective orthopaedic procedures. This risk is increased in obesity …
[HTML][HTML] Effectiveness of direct oral anticoagulants in obese adults with atrial fibrillation: a systematic review of systematic reviews and meta-analysis
Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …
Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY
AT Cohen, S Pan, W Byon, BS Ilyas, T Taylor… - Advances in Therapy, 2021 - Springer
Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …
Go big or go home: obesity and total joint arthroplasty
M Blankstein, JA Browne, KA Sonn, I Ashkenazi… - The Journal of …, 2023 - Elsevier
Obesity is highly prevalent, and it is expected to grow considerably in the United States. The
association between obesity and an increased risk of complications following total joint …
association between obesity and an increased risk of complications following total joint …
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
JS Berger, F Laliberté, A Kharat, D Lejeune… - Current Medical …, 2021 - Taylor & Francis
Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …
significantly impacted by body weight. However, real-world data are needed to better assess …
Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
MJ Alberts, J He, A Kharat, V Ashton - American Journal of Cardiovascular …, 2022 - Springer
Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …
Lifestyle changes in atrial fibrillation management and intervention
Atrial fibrillation (AF) is one of the most common arrhythmias in adults, and its continued rise
in the United States is complicated by the increased incidence and prevalence of several AF …
in the United States is complicated by the increased incidence and prevalence of several AF …
Morbidly obese patients undergoing primary total joint arthroplasty may experience higher rates of venous thromboembolism when prescribed direct oral …
TJ Humphrey, TD O'Brien, CM Melnic, KI Verrier… - The Journal of …, 2022 - Elsevier
Background Morbidly obese (body mass index [BMI]> 40 kg/m 2) patients undergoing total
joint arthroplasty (TJA) are at high risk for postoperative venous thromboembolism (VTE); …
joint arthroplasty (TJA) are at high risk for postoperative venous thromboembolism (VTE); …
Emulating a target trial to assess effect modification: an application to obesity in the comparative effectiveness and safety of apixaban versus warfarin in non-valvular …
TM Bin Hammad, E Powell, PJ Baptiste, I Douglas… - medRxiv, 2023 - medrxiv.org
Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …
Fibrinogen, coagulation, and ageing
Abstract The World Health Organization estimates that the world's population over 60 years
of age will nearly double in the next 30 years. This change imposes increasing demands on …
of age will nearly double in the next 30 years. This change imposes increasing demands on …